Identification

Name
Etacrynic acid
Accession Number
DB00903  (APRD00251)
Type
Small Molecule
Groups
Approved, Investigational
Description

A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.

Structure
Thumb
Synonyms
  • (2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy)acetic acid
  • acide étacrynique
  • ácido etacrínico
  • acidum etacrynicum
  • Etacrinic acid
  • Etakrinic acid
  • Ethacryinic Acid
  • Ethacrynate
  • Ethacrynic acid
  • Methylenebutyrylphenoxyacetic acid
External IDs
MK-595 / NSC-85791
Product Ingredients
IngredientUNIICASInChI Key
Ethacrynate sodiumK41MYV7MPM6500-81-8CWCSCNSKBSCYCS-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EdecrinTablet25 mg/1OralAvera Mc Kennan Hospital2015-10-02Not applicableUs
EdecrinTablet25 mgOralValeant Canada Lp Valeant Canada S.E.C.2004-10-15Not applicableCanada
EdecrinTablet25 mg/1OralAton Pharma, Inc.1967-01-10Not applicableUs
EdecrinTablet25 mg/1OralKaiser Foundations Hospitals2013-01-10Not applicableUs25010 0215 15 nlmimage10 a93ad486
Edecrin Tab 50mgTablet50 mgOralMerck Frosst Canada & Cie, Merck Frosst Canada & Co.1968-12-312004-03-04Canada
Ethacrynate Sodium for Injection USPPowder, for solution50 mgIntravenousSterimax Inc2018-03-29Not applicableCanada
Sodium EdecrinPowder, for solution50 mg/50mLIntravenousAton Pharma, Inc.1967-01-10Not applicableUs
Sodium EdecrinPowder, for solution50 mgIntravenousValeant Canada Lp Valeant Canada S.E.C.1968-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ethacrynate SodiumInjection, powder, lyophilized, for solution50 mg/50mLIntravenousZydus Pharmaceuticals Usa, Inc.2018-01-24Not applicableUs
Ethacrynate SodiumInjection, powder, for solution50 mg/50mLIntravenousPar Pharmaceutical2015-07-30Not applicableUs
Ethacrynate SodiumInjection, powder, lyophilized, for solution50 mg/50mLIntravenousCadila Pharnmaceuticals2018-01-24Not applicableUs
Ethacrynic AcidTablet25 mg/1OralWest Ward Pharmaceutical2017-02-24Not applicableUs
Ethacrynic AcidTablet25 mg/1OralIngenus Pharmaceuticals Nj, Llc2016-07-052018-05-11Us
Ethacrynic AcidTablet25 mg/1OralGolden State Medical Supply2017-05-04Not applicableUs
Ethacrynic AcidTablet25 mg/1OralOceanside Pharmaceuticals1967-01-10Not applicableUs
Ethacrynic AcidTablet25 mg/1OralAmneal Pharmaceuticals2018-05-14Not applicableUs
Ethacrynic AcidTablet25 mg/1OralEdenbridge Pharmaceuticals Llc2016-07-05Not applicableUs
Ethacrynic AcidTablet25 mg/1OralPar Pharmaceutical2017-07-21Not applicableUs
International/Other Brands
Crinuryl (Assia) / Edecril (Merck) / Edecrina / Endecril / Hidromedin / Hydromedin (Merck) / Mingit / Otacril / Reomax (Bioindustria) / Taladren (Malesci) / Uregit
Categories
UNII
M5DP350VZV
CAS number
58-54-8
Weight
Average: 303.138
Monoisotopic: 302.011264286
Chemical Formula
C13H12Cl2O4
InChI Key
AVOLMBLBETYQHX-UHFFFAOYSA-N
InChI
InChI=1S/C13H12Cl2O4/c1-3-7(2)13(18)8-4-5-9(12(15)11(8)14)19-6-10(16)17/h4-5H,2-3,6H2,1H3,(H,16,17)
IUPAC Name
2-[2,3-dichloro-4-(2-methylidenebutanoyl)phenoxy]acetic acid
SMILES
CCC(=C)C(=O)C1=C(Cl)C(Cl)=C(OCC(O)=O)C=C1

Pharmacology

Indication

For the treatment of high blood pressure and edema caused by diseases like congestive heart failure, liver failure, and kidney failure.

Associated Conditions
Pharmacodynamics

Ethacrynic acid is a monosulfonamyl loop or high ceiling diuretic. Ethacrynic acid acts on the ascending limb of the loop of Henle and on the proximal and distal tubules. Urinary output is usually dose dependent and related to the magnitude of fluid accumulation. Water and electrolyte excretion may be increased several times over that observed with thiazide diuretics, since ethacrynic acid inhibits reabsorption of a much greater proportion of filtered sodium than most other diuretic agents. Therefore, ethacrynic acid is effective in many patients who have significant degrees of renal insufficiency. Ethacrynic acid has little or no effect on glomerular filtration or on renal blood flow, except following pronounced reductions in plasma volume when associated with rapid diuresis.

Mechanism of action

Ethacrynic acid inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. Diuretics also lower blood pressure initially by reducing plasma and extracellular fluid volume; cardiac output also decreases, explaining its antihypertensive action. Eventually, cardiac output returns to normal with an accompanying decrease in peripheral resistance. Its mode of action does not involve carbonic anhydrase inhibition.

TargetActionsOrganism
ASodium/potassium-transporting ATPase subunit alpha-1
inhibitor
Human
ASolute carrier family 12 member 1
inhibitor
Human
ULymphoid enhancer-binding factor 1Not AvailableHuman
UGlutathione S-transferase P
inhibitor
Human
Absorption

Onset of action is rapid, usually within 30 minutes after an oral dose of ethacrynic acid or within 5 minutes after an intravenous injection of ethacrynic acid.

Volume of distribution
Not Available
Protein binding

> 98%

Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Overdosage may lead to excessive diuresis with electrolyte depletion.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Ethacrynic Acid Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINEThe therapeutic efficacy of (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE can be decreased when used in combination with Etacrynic acid.Experimental
(4R)-limoneneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Etacrynic acid.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Etacrynic acid.Investigational
5-androstenedione5-androstenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
AbediterolAbediterol may increase the hypokalemic activities of Etacrynic acid.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.Approved, Investigational
AcebutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acebutolol.Approved, Investigational
AceclofenacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Etacrynic acid.Approved, Investigational
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etacrynic acid.Approved, Investigational, Withdrawn
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Adapalene.Approved
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Etacrynic acid.Experimental, Investigational
AlclofenacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Etacrynic acid.Approved
AlcuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Etacrynic acid.Approved
AldosteroneAldosterone may increase the hypokalemic activities of Etacrynic acid.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Aliskiren.Approved, Investigational
AllicinThe therapeutic efficacy of Allicin can be decreased when used in combination with Etacrynic acid.Investigational
AllopurinolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etacrynic acid.Approved
AloxiprinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Etacrynic acid.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Etacrynic acid.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Etacrynic acid.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Etacrynic acid.Approved, Investigational
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Etacrynic acid.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Etacrynic acid.Approved
Aminosalicylic AcidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Etacrynic acid.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Etacrynic acid.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Etacrynic acid.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Amyl Nitrite.Approved
AndrographolideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Etacrynic acid.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Etacrynic acid.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Etacrynic acid.Investigational
AnisodamineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Etacrynic acid.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Apraclonidine.Approved
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Etacrynic acid.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Apremilast.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Etacrynic acid.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Etacrynic acid.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Etacrynic acid.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Etacrynic acid.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Etacrynic acid.Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Etacrynic acid.Approved
AtracuriumEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylateEtacrynic acid may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Azilsartan medoxomil.Approved, Investigational
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Etacrynic acid.Investigational
BalsalazideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Etacrynic acid.Experimental
BarbitalBarbital may increase the hypotensive activities of Etacrynic acid.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Etacrynic acid.Approved
Beclomethasone dipropionateBeclomethasone dipropionate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Etacrynic acid.Experimental
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Etacrynic acid.Investigational
BenazeprilEtacrynic acid may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bendazac.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Etacrynic acid.Approved
BenorilateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Benzydamine.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Etacrynic acid.Approved, Withdrawn
BetamethasoneBetamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Etacrynic acid.Approved, Investigational
BevoniumThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Etacrynic acid.Experimental, Illicit, Withdrawn
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Etacrynic acid.Approved
BitolterolBitolterol may increase the hypokalemic activities of Etacrynic acid.Withdrawn
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Etacrynic acid.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Etacrynic acid.Approved
BromfenacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Etacrynic acid.Approved, Investigational
BucillamineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bucillamine.Investigational
BudesonideBudesonide may increase the hypokalemic activities of Etacrynic acid.Approved
BufexamacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Etacrynic acid.Investigational, Withdrawn
BumadizoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Bumadizone.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Etacrynic acid.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Etacrynic acid.Approved, Investigational
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etacrynic acid.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Etacrynic acid.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Etacrynic acid.Approved
CandoxatrilEtacrynic acid may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilEtacrynic acid may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Etacrynic acid.Approved, Investigational
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Etacrynic acid.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Etacrynic acid.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Etacrynic acid.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Carvedilol.Approved, Investigational
CastanospermineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
ChloroquineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Etacrynic acid.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etacrynic acid.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Etacrynic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etacrynic acid.Experimental
CilazaprilEtacrynic acid may increase the hypotensive activities of Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Etacrynic acid.Approved, Investigational
CisatracuriumEtacrynic acid may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Etacrynic acid is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Clevidipine.Approved, Investigational
ClobetasolClobetasol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Etacrynic acid.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Etacrynic acid.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Etacrynic acid.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Etacrynic acid.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Etacrynic acid.Approved, Investigational, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Etacrynic acid.Approved
ClonixinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Clonixin.Approved
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Etacrynic acid.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etacrynic acid.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etacrynic acid.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Etacrynic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Etacrynic acid.Approved, Investigational
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Etacrynic acid.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Etacrynic acid.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
CurcuminThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Curcumin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Etacrynic acid.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dapagliflozin.Approved
DecamethoniumEtacrynic acid may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DelaprilEtacrynic acid may increase the hypotensive activities of Delapril.Investigational
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Etacrynic acid.Investigational
DersalazineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid.Approved
DeslanosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Etacrynic acid.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Etacrynic acid.Experimental, Vet Approved
DexamethasoneDexamethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Etacrynic acid.Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Etacrynic acid.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Etacrynic acid.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Etacrynic acid.Approved, Investigational
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Etacrynic acid.Experimental
DiclofenacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Diclofenamide.Approved, Investigational
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Etacrynic acid.Approved
DifenpiramideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Etacrynic acid.Approved
DiflunisalThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Etacrynic acid.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etacrynic acid.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Etacrynic acid.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Etacrynic acid.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Etacrynic acid.Investigational, Vet Approved
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Etacrynic acid.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dinutuximab.Approved, Investigational
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Etacrynic acid.Experimental
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etacrynic acid.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Etacrynic acid.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Dipyridamole.Approved
DobutamineDobutamine may increase the hypokalemic activities of Etacrynic acid.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Etacrynic acid is combined with Dofetilide.Approved, Investigational
Domoic AcidEtacrynic acid may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
DoxacuriumEtacrynic acid may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Etacrynic acid.Experimental
DroxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
DuloxetineEtacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with E-6201.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Etacrynic acid.Approved, Investigational
EmpagliflozinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Empagliflozin.Approved
EnalaprilEtacrynic acid may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatEtacrynic acid may increase the hypotensive activities of Enalaprilat.Approved
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Etacrynic acid.Experimental
EphedraEphedra may increase the hypokalemic activities of Etacrynic acid.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Epirizole.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Etacrynic acid.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Etacrynic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Etacrynic acid.Approved
EquileninEquilenin may increase the hypokalemic activities of Etacrynic acid.Experimental
EquilinEquilin may increase the hypokalemic activities of Etacrynic acid.Approved
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Etacrynic acid.Approved
EstroneEstrone may increase the hypokalemic activities of Etacrynic acid.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtafedrineEtafedrine may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ethenzamide.Experimental
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Etacrynic acid.Withdrawn
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Etacrynic acid.Approved, Illicit
EtodolacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Etacrynic acid.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
ExisulindThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Felbinac.Experimental
FelodipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.Approved, Investigational
FenbufenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenbufen.Approved
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Etacrynic acid.Approved
FenoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etacrynic acid.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Etacrynic acid.Approved, Investigational
FloctafenineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Etacrynic acid.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Etacrynic acid.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FlunixinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FluprednideneFluprednidene may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Etacrynic acid.Approved
FlurbiprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Etacrynic acid.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Etacrynic acid.Approved
Fluticasone propionateFluticasone propionate may increase the hypokalemic activities of Etacrynic acid.Approved
FormestaneFormestane may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
FoscarnetEtacrynic acid may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilEtacrynic acid may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Etacrynic acid.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Etacrynic acid.Approved
FurosemideFurosemide may increase the ototoxic activities of Etacrynic acid.Approved, Vet Approved
GallamineEtacrynic acid may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodideEtacrynic acid may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Etacrynic acid.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Etacrynic acid.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Etacrynic acid.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Gitoformate.Experimental
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etacrynic acid.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Etacrynic acid.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Etacrynic acid.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etacrynic acid.Approved
GuacetisalThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Guacetisal.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Guanfacine.Approved, Investigational
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Etacrynic acid.Investigational
HalcinonideHalcinonide may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid.Approved, Vet Approved
HE3286HE3286 may increase the hypokalemic activities of Etacrynic acid.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Etacrynic acid.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Etacrynic acid.Approved
HexoprenalineHexoprenaline may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Higenamine.Investigational
HydralazineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Etacrynic acid.Approved, Illicit
HydrocortisoneHydrocortisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Etacrynic acid.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etacrynic acid.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Etacrynic acid.Vet Approved
IbuprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Icatibant.Approved, Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Etacrynic acid.Approved, Investigational
ImidaprilEtacrynic acid may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Etacrynic acid.Approved
IndacaterolIndacaterol may increase the hypokalemic activities of Etacrynic acid.Approved
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Etacrynic acid.Approved
IndobufenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Indoprofen.Withdrawn
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Etacrynic acid.Withdrawn
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etacrynic acid.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Etacrynic acid.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etacrynic acid.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Etacrynic acid.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Etacrynic acid.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etacrynic acid.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etacrynic acid.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Irbesartan.Approved, Investigational
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Etacrynic acid.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Etacrynic acid.Approved
IsoetarineIsoetarine may increase the hypokalemic activities of Etacrynic acid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Etacrynic acid.Approved, Vet Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Etacrynic acid.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isosorbide Mononitrate.Approved
IsoxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Isoxicam.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid.Approved, Investigational
IstaroximeIstaroxime may increase the hypokalemic activities of Etacrynic acid.Investigational
IvabradineEtacrynic acid may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Etacrynic acid.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Etacrynic acid.Approved, Investigational
KetoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ketorolac.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Etacrynic acid.Approved
LacidipineEtacrynic acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Leflunomide.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Etacrynic acid.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Etacrynic acid.Approved, Investigational
LevodopaEtacrynic acid may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Etacrynic acid.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etacrynic acid.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Etacrynic acid.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Etacrynic acid.Approved
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Etacrynic acid.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Etacrynic acid.Approved
LisinoprilEtacrynic acid may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be decreased when it is combined with Etacrynic acid.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Etacrynic acid.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Etacrynic acid.Approved, Investigational
LonazolacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Etacrynic acid.Approved
LoteprednolLoteprednol may increase the hypokalemic activities of Etacrynic acid.Approved
LoxoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Magnesium salicylate.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Etacrynic acid.Approved, Investigational
MasoprocolThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Etacrynic acid.Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Etacrynic acid.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Etacrynic acid.Approved
Mefenamic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Etacrynic acid.Vet Approved
MeloxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Etacrynic acid.Experimental
MesalazineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Etacrynic acid.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etacrynic acid.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Etacrynic acid.Approved, Illicit
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Etacrynic acid.Approved
MethohexitalMethohexital may increase the hypotensive activities of Etacrynic acid.Approved
MethotrexateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methotrexate.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Etacrynic acid.Approved
Methyl salicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Methyldopa.Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Etacrynic acid.Approved
MethylprednisoloneMethylprednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Metipranolol.Approved
MetocurineEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodideEtacrynic acid may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Etacrynic acid.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Etacrynic acid.Approved, Investigational
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Etacrynic acid.Experimental
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etacrynic acid.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Etacrynic acid.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Etacrynic acid.Approved, Investigational
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
MivacuriumEtacrynic acid may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mizoribine.Investigational
MoexiprilEtacrynic acid may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etacrynic acid.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Etacrynic acid.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Etacrynic acid.Approved, Investigational
NabumetoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nabumetone.Approved
NadololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nadolol.Approved
NafamostatThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etacrynic acid.Approved
NaproxenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
NCX 1022NCX 1022 may increase the hypokalemic activities of Etacrynic acid.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Etacrynic acid.Experimental
NebivololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nebivolol.Approved, Investigational
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Etacrynic acid.Approved, Vet Approved
NeosaxitoxinEtacrynic acid may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nepafenac.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nesiritide.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Etacrynic acid.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Etacrynic acid.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Etacrynic acid.Experimental
NicorandilNicorandil may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
NifedipineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nifedipine.Approved
NifenazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Niflumic Acid.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Etacrynic acid.Approved, Investigational
NimesulideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Etacrynic acid.Approved, Investigational
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Etacrynic acid.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Etacrynic acid.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Etacrynic acid.Approved
NitroaspirinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Nitroaspirin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Etacrynic acid.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Etacrynic acid.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Nitrous acid is combined with Etacrynic acid.Approved, Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Etacrynic acid.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Etacrynic acid.Approved, Illicit
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Etacrynic acid.Approved, Investigational
OleandrinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Etacrynic acid.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Etacrynic acid.Approved, Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Etacrynic acid.Approved
OlopatadineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Olsalazine.Approved
OmapatrilatEtacrynic acid may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Etacrynic acid.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Etacrynic acid.Approved
OrgoteinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxaprozin.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Etacrynic acid.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etacrynic acid.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etacrynic acid.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etacrynic acid.Approved, Vet Approved
PalmidrolThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pancuronium.Approved
PapaverineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Papaverine.Approved, Investigational
ParamethasoneParamethasone may increase the hypokalemic activities of Etacrynic acid.Approved
ParecoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Parecoxib.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
ParthenolideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Parthenolide.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Penbutolol.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etacrynic acid.Approved, Vet Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Investigational, Vet Approved
PerindoprilEtacrynic acid may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etacrynic acid.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Etacrynic acid.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Etacrynic acid.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Etacrynic acid.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Etacrynic acid.Approved, Investigational, Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Etacrynic acid.Approved, Investigational
PhenobarbitalPhenobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Etacrynic acid.Experimental
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Etacrynic acid.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Etacrynic acid.Approved, Investigational
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Etacrynic acid.Approved
Phenyl aminosalicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Etacrynic acid.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PindololThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Pindolol.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Etacrynic acid.Approved, Investigational
PipecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Etacrynic acid.Approved
PirfenidoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Etacrynic acid.Approved, Investigational
PiroxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pirprofen.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Etacrynic acid.Approved, Investigational
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Etacrynic acid.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
PranoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Etacrynic acid.Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Etacrynic acid.Approved
PrednicarbatePrednicarbate may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
PrednisolonePrednisolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Etacrynic acid.Approved, Experimental, Investigational
PrimidonePrimidone may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Etacrynic acid.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Etacrynic acid.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Etacrynic acid.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
PTC299The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Etacrynic acid.Experimental
PyrantelEtacrynic acid may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuetiapineThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Quetiapine.Approved
QuinaprilEtacrynic acid may increase the hypotensive activities of Quinapril.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Etacrynic acid.Approved
RamiprilEtacrynic acid may increase the hypotensive activities of Ramipril.Approved
RapacuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Etacrynic acid.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etacrynic acid.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
RescinnamineEtacrynic acid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etacrynic acid.Approved, Investigational
ResveratrolThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Etacrynic acid.Approved
RiociguatThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Riociguat.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Etacrynic acid.Approved, Investigational
RocuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Ropinirole is combined with Etacrynic acid.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Etacrynic acid.Approved
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etacrynic acid.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Rotigotine is combined with Etacrynic acid.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Etacrynic acid.Approved
SalbutamolSalbutamol may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolSalmeterol may increase the hypokalemic activities of Etacrynic acid.Approved
SalsalateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etacrynic acid.Approved
SecobarbitalSecobarbital may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Etacrynic acid.Approved, Investigational, Vet Approved
SemapimodThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etacrynic acid.Approved, Vet Approved
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Etacrynic acid.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etacrynic acid.Approved, Investigational
Sodium phosphate, monobasicEtacrynic acid may increase the nephrotoxic activities of Sodium phosphate.Approved
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Etacrynic acid.Investigational
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Etacrynic acid.Approved
SpiraprilEtacrynic acid may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.Approved
SRT501The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Etacrynic acid.Approved, Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Etacrynic acid.Approved, Vet Approved
SuccinylcholineEtacrynic acid may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Tamsulosin is combined with Etacrynic acid.Approved, Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Etacrynic acid.Approved
TarenflurbilThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tarenflurbil.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Telmisartan.Approved, Investigational
TemocaprilEtacrynic acid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tepoxalin.Vet Approved
TerazosinThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Terazosin.Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Etacrynic acid.Approved
TeriflunomideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Etacrynic acid.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Etacrynic acid.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etacrynic acid.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Etacrynic acid.Experimental
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Etacrynic acid.Approved
TinoridineThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tinoridine.Investigational
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Etacrynic acid.Experimental
TixocortolTixocortol may increase the hypokalemic activities of Etacrynic acid.Approved, Withdrawn
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Etacrynic acid.Approved, Investigational
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Etacrynic acid.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Tolazoline is combined with Etacrynic acid.Approved, Vet Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etacrynic acid.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Etacrynic acid.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tolmetin.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Etacrynic acid is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Etacrynic acid.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etacrynic acid.Approved, Investigational
TrandolaprilEtacrynic acid may increase the hypotensive activities of Trandolapril.Approved
TranilastThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Etacrynic acid.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Etacrynic acid.Approved, Investigational, Nutraceutical
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Etacrynic acid.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Etacrynic acid.Approved
TribenosideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Triptolide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Etacrynic acid.Investigational, Withdrawn
Trolamine salicylateThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarineEtacrynic acid may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Etacrynic acid.Approved
ValdecoxibThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid.Approved, Investigational
VecuroniumEtacrynic acid may decrease the neuromuscular blocking activities of Vecuronium.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Etacrynic acid.Approved
VilanterolVilanterol may increase the hypokalemic activities of Etacrynic acid.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etacrynic acid.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Etacrynic acid.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Etacrynic acid.Approved
ZaltoprofenThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilEtacrynic acid may increase the hypotensive activities of Zofenopril.Experimental
ZomepiracThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
  • Take with food to reduce irritation.

References

Synthesis Reference

Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB0015039
KEGG Drug
D00313
PubChem Compound
3278
PubChem Substance
46507562
ChemSpider
3163
BindingDB
50186231
ChEBI
4876
ChEMBL
CHEMBL456
Therapeutic Targets Database
DAP000748
PharmGKB
PA449518
HET
EAA
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Ethacrynic_acid
ATC Codes
C03CC01 — Etacrynic acid
AHFS Codes
  • 40:28.08 — Loop Diuretics
PDB Entries
11gs / 1gse / 1gsf / 2gss / 3dgq / 3gss / 3hjo / 3km6 / 3kmo / 3n9j
FDA label
Download (75.2 KB)
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentBladder Cancers1
1, 2CompletedOtherGlaucoma1
3CompletedTreatmentFluid Overload1

Pharmacoeconomics

Manufacturers
  • Aton pharma inc
Packagers
  • Aton Pharma Inc.
  • Ben Venue Laboratories Inc.
  • Draxis Specialty Pharmaceuticals Inc.
  • DSM Corp.
  • Kaiser Foundation Hospital
  • Merck & Co.
  • Professional Co.
Dosage forms
FormRouteStrength
TabletOral25 mg
TabletOral25 mg/1
TabletOral50 mg
Injection, powder, for solutionIntravenous50 mg/50mL
Injection, powder, lyophilized, for solutionIntravenous50 mg/50mL
Powder, for solutionIntravenous50 mg/50mL
Powder, for solutionIntravenous50 mg
Prices
Unit descriptionCostUnit
Sodium edecrin 50 mg vial527.4USD vial
Edecrin sodium 50 mg vial114.0USD vial
Ethacrynic acid 100% powder26.4USD g
Edecrin 25 mg tablet3.19USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)118.5-120.5Schultz, E.M. and Sprague, J.M.; U.S. Patent 3,255,241; June 7, 1966; assigned to Merck & co., Inc.
logP3.3Not Available
pKa3.5MERCK INDEX (2001)
Predicted Properties
PropertyValueSource
Water Solubility0.0194 mg/mLALOGPS
logP3.42ALOGPS
logP3.66ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)2.8ChemAxon
pKa (Strongest Basic)-5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area63.6 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity72.22 m3·mol-1ChemAxon
Polarizability28.57 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9591
Blood Brain Barrier-0.6921
Caco-2 permeable+0.5597
P-glycoprotein substrateSubstrate0.54
P-glycoprotein inhibitor INon-inhibitor0.5574
P-glycoprotein inhibitor IINon-inhibitor0.9828
Renal organic cation transporterNon-inhibitor0.9052
CYP450 2C9 substrateNon-substrate0.8508
CYP450 2D6 substrateNon-substrate0.8947
CYP450 3A4 substrateNon-substrate0.5262
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorInhibitor0.8949
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8384
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8344
BiodegradationReady biodegradable0.6545
Rat acute toxicity2.4505 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9228
hERG inhibition (predictor II)Non-inhibitor0.9044
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0690000000-f598b8bee69a6b62e817
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0fb9-2930000000-143e32f52c12761e81dd

Taxonomy

Description
This compound belongs to the class of organic compounds known as chlorophenoxyacetates. These are compounds containing a phenoxyacetate that carries one or more chlorine atoms on the benzene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Phenoxyacetic acid derivatives
Direct Parent
Chlorophenoxyacetates
Alternative Parents
Butyrophenones / Aryl ketones / Benzoyl derivatives / Dichlorobenzenes / Phenol ethers / Phenoxy compounds / Alkyl aryl ethers / Alpha-branched alpha,beta-unsaturated ketones / Aryl chlorides / Enones
show 7 more
Substituents
Chlorophenoxyacetate / Butyrophenone / 1,2-dichlorobenzene / Phenoxy compound / Benzoyl / Phenol ether / Aryl ketone / Halobenzene / Chlorobenzene / Alkyl aryl ether
show 20 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, monocarboxylic acid, dichlorobenzene, aromatic ketone (CHEBI:4876)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Steroid hormone binding
Specific Function
This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
Gene Name
ATP1A1
Uniprot ID
P05023
Uniprot Name
Sodium/potassium-transporting ATPase subunit alpha-1
Molecular Weight
112895.01 Da
References
  1. Ronquist G, Agren GK: A Mg2+- and Ca2+-stimulated adenosine triphosphatase at the outer surface of Ehrlich ascites tumor cells. Cancer Res. 1975 Jun;35(6):1402-6. [PubMed:124205]
  2. Proverbio F, Condrescu-Guidi M, Whittembury G: Ouabain-insensitive Na+ stimulation of an Mg-2+ -dependent ATPase in kidney tissue. Biochim Biophys Acta. 1975 Jun 25;394(2):281-92. [PubMed:124600]
  3. Valdes RM, Huff MO, El-Masri MA, El-Mallakh RS: Effect of ethacrynic acid on sodium pump alpha isoforms in SH-SY5Y cells. Bipolar Disord. 2003 Apr;5(2):123-8. [PubMed:12680902]
  4. Kiil F, Sejersted OM: Analysis of energy metabolism and mechanism of loop diuretics in the thick ascending limb of Henle's loop in dog kidneys. Acta Physiol Scand. 2003 May;178(1):73-82. [PubMed:12713517]
  5. Schurek HJ, Aulbert E, Ebel H, Muller-Suur C: Influence of ouabain and ethacrynic acid on sodium transport and NaK-ATPase activity in the isolated perfused rat kidney. Curr Probl Clin Biochem. 1975;4:162-8. [PubMed:127690]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Bowes TJ, Gupta RS: Induction of mitochondrial fusion by cysteine-alkylators ethacrynic acid and N-ethylmaleimide. J Cell Physiol. 2005 Mar;202(3):796-804. [PubMed:15389563]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Participates in the Wnt signaling pathway. Activates transcription of target genes in the presence of CTNNB1 and EP300. May play a role in hair cell differentiation and follicle morphogenesis. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by LEF1 and CTNNB1. Regulates T-cell receptor alpha enhancer function. Binds DNA in a sequence-specific manner. PIAG antagonizes both Wnt-dependent and Wnt-independent activation by LEF1 (By similarity). Isoform 3 lacks the CTNNB1 interaction domain and may be an antagonist for Wnt signaling. Isoform 5 transcriptionally activates the fibronectin promoter, binds to and represses transcription from the E-cadherin promoter in a CTNNB1-independent manner, and is involved in reducing cellular aggregation and increasing cell migration of pancreatic cancer cells. Isoform 1 transcriptionally activates MYC and CCND1 expression and enhances proliferation of pancreatic tumor cells.
Specific Function
Armadillo repeat domain binding
Gene Name
LEF1
Uniprot ID
Q9UJU2
Uniprot Name
Lymphoid enhancer-binding factor 1
Molecular Weight
44200.41 Da
References
  1. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, Schmidt-Wolf IG, Kipps TJ, Carson DA: Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009 Dec 14;4(12):e8294. doi: 10.1371/journal.pone.0008294. [PubMed:20011538]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
Curator comments
irreversible inhibitor
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles.
Gene Name
GSTA2
Uniprot ID
P09210
Uniprot Name
Glutathione S-transferase A2
Molecular Weight
25663.675 Da
References
  1. Depeille P, Cuq P, Passagne I, Evrard A, Vian L: Combined effects of GSTP1 and MRP1 in melanoma drug resistance. Br J Cancer. 2005 Jul 25;93(2):216-23. [PubMed:15999103]
  2. Awasthi S, Srivastava SK, Ahmad F, Ahmad H, Ansari GA: Interactions of glutathione S-transferase-pi with ethacrynic acid and its glutathione conjugate. Biochim Biophys Acta. 1993 Jul 10;1164(2):173-8. [PubMed:8329448]
  3. Iersel ML, Ploemen JP, Struik I, van Amersfoort C, Keyzer AE, Schefferlie JG, van Bladeren PJ: Inhibition of glutathione S-transferase activity in human melanoma cells by alpha,beta-unsaturated carbonyl derivatives. Effects of acrolein, cinnamaldehyde, citral, crotonaldehyde, curcumin, ethacrynic acid, and trans-2-hexenal. Chem Biol Interact. 1996 Oct 21;102(2):117-32. [PubMed:8950226]
  4. van Iersel ML, Ploemen JP, Lo Bello M, Federici G, van Bladeren PJ: Interactions of alpha, beta-unsaturated aldehydes and ketones with human glutathione S-transferase P1-1. Chem Biol Interact. 1997 Dec 12;108(1-2):67-78. [PubMed:9463521]
  5. Morrow CS, Smitherman PK, Townsend AJ: Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol. 1998 Oct 15;56(8):1013-21. [PubMed:9776312]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bertucci C, Nanni B, Raffaelli A, Salvadori P: Chemical modification of human albumin at cys34 by ethacrynic acid: structural characterisation and binding properties. J Pharm Biomed Anal. 1998 Oct;18(1-2):127-36. [PubMed:9863950]
  2. Bertucci C, Wainer IW: Improved chromatographic performance of a modified human albumin based stationary phase. Chirality. 1997;9(4):335-40. [PubMed:9275312]
  3. Fehske KJ, Muller WE: High-affinity binding of ethacrynic acid is mediated by the two most important drug binding sites of human serum albumin. Pharmacology. 1986;32(4):208-13. [PubMed:3714803]
  4. Lebedev AA, Samokrutova OV: [Study of the binding of diuretics by serum proteins according to changes in tryptophan fluorescence]. Farmakol Toksikol. 1989 May-Jun;52(3):40-3. [PubMed:2792351]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Sekine T, Watanabe N, Hosoyamada M, Kanai Y, Endou H: Expression cloning and characterization of a novel multispecific organic anion transporter. J Biol Chem. 1997 Jul 25;272(30):18526-9. [PubMed:9228014]

Drug created on June 13, 2005 07:24 / Updated on July 18, 2018 19:29